Nortrachelogenin
Catalog No: CFN98454
Nortrachelogenin is a novel agent for prostate cancer therapy with ability to inhibit Akt membrane localization and activity as well as the activation of growth factor receptors, thereby efficiently synergizing with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), exposure.Nortrachelogenin has anti-inflammatory properties,it shows moderate inhibiting activities on NF- κB signaling pathway induced by TNF-α , with the IC50 value of 49.4 uM. Nortrachelogenin also shows anti-plasmodium activity of 14.50 dg/ml. (+ )-Nortrachelogenin shows effects on the central nervous system producing depression in rabbits, it is moderately active against HIV-1 in vitro. (-)-Nortrachelogenin exerts its antibacterial effect by disorganizing and perturbing the cytoplasmic membrane, it also can induce membrane disruption and caspase-dependent apoptosis.
Buddlejasaponin IV
Catalog No: CFN98519
Buddlejasaponin IV has analgesic and anti-inflammatory effects, the inhibitions of the expressions of iNOS, COX-2, TNF-alpha, IL-1beta and IL-6 by blocking NF-kappaB activation. Buddlejasaponin IV exerts cytotoxic effects against cancer cells,it can induce cell cycle arrest at G2/M phase and apoptosis in immortalized human oral keratinocytes, it may possess antimetastatic potential by inducing anoikis and upregulating NAG-1 expression. Buddlejasaponin IV can inhibit intrinsic and extrinsic hyperlipidemia and hypercholesterolemia in the rat.
